Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Its products include ADCETRIS, for the treatment of classical Hodgkin lymphoma (cHL), systemic anaplastic large cell lymphoma (sALCL), and other CD30-expressing peripheral T-cell lymphomas (PTCL); PADCEV, indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC); TUKYSA for the treatment of adult patients with advanced unrespectable or metastatic HER2-positive breast cancer, including patients with brain metastases; and TIVDAK for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. The company also specializes in antibody-drug conjugate (ADC) and sugar-engineered antibody (SEA) technologies.